Maxigen Biotech Inc. (TPE:1783)

Maxigen Biotech Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	291.2	265.31	190.17	165.83	139.4	87.67
Depreciation & Amortization	36.5	32.03	26.85	27.24	29.05	32.31
Other Amortization	0.11	0.11	0.18	0.37	0.53	0.59
Loss (Gain) From Sale of Assets	-	-	0	-13.62	-1.03	-
Stock-Based Compensation	2.17	3.13	6.69	7.69	13.48	2.45
Provision & Write-off of Bad Debts	5.94	-7.32	14.47	0.2	4.72	3.02
Other Operating Activities	-5.41	5.75	4.78	-5.4	15.37	1.28
Change in Accounts Receivable	-38.8	-31.02	-29.78	-3.8	-12.26	-6
Change in Inventory	-17.45	-23.46	9.45	-9.91	3.68	8.03
Change in Accounts Payable	46.98	36.84	32.87	-18.82	-4.11	7.05
Change in Unearned Revenue	-0.9	-7.83	21.6	-2.92	-6.88	7.36
Change in Other Net Operating Assets	14.42	16.69	20.96	24.33	86.38	-26.18
Operating Cash Flow	334.74	290.22	298.22	171.2	268.34	117.59
Operating Cash Flow Growth	7.89%	-2.68%	74.20%	-36.20%	128.19%	57.71%

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-91.1	-81.87	-31.77	-22.44	-14.29	-14.26
Sale of Property, Plant & Equipment	-	-	-	0.9	6.28	-
Sale (Purchase) of Intangibles	-0.77	-0.77	-	-	-0.15	-1.19
Sale (Purchase) of Real Estate	-	-	-	22.59	-	-
Investment in Securities	-250	-300	-	-491.27	16.56	-13.74
Other Investing Activities	3.82	-0.36	2.7	-0.03	2.04	26.41
Investing Cash Flow	-338.04	-382.99	-29.07	-490.25	10.43	-2.78

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Short-Term Debt Issued	-	100	-	-	-	-
Total Debt Issued	100	100	-	-	-	-
Long-Term Debt Repaid	-	-	-	-	-0.95	-2.49
Net Debt Issued (Repaid)	100	100	-	-	-0.95	-2.49
Issuance of Common Stock	0.59	0.39	28.69	0.96	-	247.35
Common Dividends Paid	-74.43	-74.43	-88.96	-42.35	-	-56.27
Dividends Paid	-74.43	-74.43	-88.96	-42.35	-	-56.27
Other Financing Activities	-3.58	4.7	0.54	-	-0.1	0.1
Financing Cash Flow	22.57	30.66	-59.73	-41.39	-1.05	188.69

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	-11.28	-0.75	-1.45	0.57	-0.08	0.03
Net Cash Flow	7.99	-62.86	207.97	-359.87	277.64	303.54

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	243.64	208.36	266.45	148.76	254.05	103.34
Free Cash Flow Growth	-10.65%	-21.80%	79.12%	-41.44%	145.85%	61.91%
Free Cash Flow Margin	29.09%	25.67%	39.15%	23.91%	42.03%	20.18%
Free Cash Flow Per Share	2.69	2.31	2.97	1.66	2.84	1.22
Levered Free Cash Flow	219.65	105.01	186.08	91.4	209.69	71.5
Unlevered Free Cash Flow	219.77	105.03	186.08	91.4	209.73	71.62

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	0.04	0.04	-	-	0.07	0.2
Cash Income Tax Paid	33.83	33.83	30.6	32.72	10.76	8.52
Change in Working Capital	4.24	-8.78	55.09	-11.12	66.81	-9.73

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 17, 2026

Data Sources Report a data error